21 Sept 2026
46 - New frontiers in PCOS management (23 min)
Polycystic Ovarian Syndrome (PCOS) is a common hormonal and metabolic disorder affecting millions of women, yet a staggering number of cases go undiagnosed. Now, a proposed name change and new diagnostic tools are set to redefine how this complex condition is managed. In this episode, Maeson Latsko, PhD is joined by Marco Marcelli, MD, a board-certified endocrinologist and Medical Director in Research and Development at Quest Diagnostics. They explore the clinical shift toward recognizing PCOS as a metabolic condition, the evolution of diagnostic standards from the Rotterdam criteria to new international guidelines, the pivotal role of AMH blood testing as a noninvasive alternative to ultrasound, and what emerging global data reveals about the true prevalence and presentation of the syndrome.
This episode will
Discuss the clinical reasoning behind the proposed name change from Polycystic Ovarian Syndrome (PCOS) to Polyendocrine Metabolic Ovarian Syndrome (PMOS) and its implications for managing the condition (3:00)
Review the evolution of diagnostic criteria, from the 2003 Rotterdam consensus to the 2023 international guidelines that established Anti-Müllerian Hormone (AMH) as a non-invasive alternative to ultrasound (6:30)
Explore emerging global data on the prevalence and phenotypic expression of PCOS, highlighting significant variations across diverse ethnic populations and the impact of cultural practices on diagnosis (15:00)
Describe the clinical significance and approach for patients who present with isolated polycystic ovarian morphology (PCOM) on an ultrasound but lack other traditional symptoms of PCOS (18:00)
Speakers: Marco Marcelli, MD; Maeson Latsko, PhD
Contributors: Maeson Latsko, PhD; Marco Marcelli, MD; Gregory Buchan, PhD; Trisha Winchester, PhD, MBA; Abhi Patel; Sanjay Dixit, MD; Millicent Kee, MSN, APRN, FNP-BC
Ordering information
Hyperandrogenism: Testosterone, Free (Dialysis) and Total, MS
Hyperandrogenism: Testosterone, Free (Dialysis), Total (MS) and Sex Hormone Binding Globulin
PCOM: Anti-Mullerian Hormone (AMH), Female
Thyroid disease: TSH
Congenital adrenal hyperplasia: 17-Hydroxyprogesterone
Hyperprolactinemia: Prolactin
Additional resources
PCOS Test Guide
Quest Diagnostics Polycystic ovary syndrome
Clinical Focus: Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) Diagnostic Algorithm
Laboratory Testing in the Differential Diagnosis of PCOS and NCCAH
Podcast: Laboratory assessment in PCOS diagnosis and management
References
Naeem I, Zehra A, Rehman F, et al. Polycystic ovarian syndrome a risk factor for non-communicable diseases: insights into recent research and prevention approaches. J Ovarian Res. 2025;18(1):219. doi:10.1186/s13048-025-01741-z
Teede HJ, Tay CT, Laven JJE, et al. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108(10):2447-2469. doi:10.1210/clinem/dgad463
Teede HJ, Khomami MB, Morman R, et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026;407(10545):2329-2339. doi:10.1016/S0140-6736(26)00717-8
Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19(1):41-47. doi:10.1093/humrep/deh098
Makwe CC, Olamijulo JA, Balogun MR, Akinkugbe AO, Samuel TA, Udenze JC, Brill F, Marcelli M, Dixit SB, Larsen J, Adeyemo MA, Bi C, Buyalos SP, and Azziz R. Diagnostic Accuracy of Anti-Müllerian Hormone (AMH) for Polycystic Ovarian Morphology (PCOM) and Polycystic Ovary Syndrome (PCOS) in a Nigerian Population-Based Cohort. Accessed preprint. J Endocr Soc. Expected publication date: October 2026
